FDA hands Gilead a stun­ning re­jec­tion for block­buster RA can­di­date fil­go­tinib, deal­ing CEO O’Day a ma­jor set­back

In a sur­prise twist, the FDA has re­ject­ed Gilead’s mar­ket­ing ap­pli­ca­tion for fil­go­tinib, deal­ing a body blow to Daniel O’Day’s hopes for a rapid im­prove­ment in the big biotech’s drug port­fo­lio with a block­buster ad­di­tion.

Late on Tues­day, Gilead $GILD put out word that the agency had turned thumbs-down on their ap­pli­ca­tion for rheuma­toid arthri­tis, say­ing that reg­u­la­tors want­ed to see more da­ta from two on­go­ing safe­ty stud­ies of the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER